Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Radiotherapy 35Doxorubicin 30Ifosfamide 29Cyclophosphamide 24Vincristine 23Filgrastim 23Etoposide 20Temozolomide 14Granulocyte Colony-Stimulating Factor 14Dactinomycin 11Cisplatin 11Trabectedin 10Methotrexate 10Gene Expression Profiling 10Radiation 9Imatinib Mesylate 9Surgical Procedures, Operative 8Polymerase Chain Reaction 8Irinotecan 8Specimen Handling 7Paclitaxel 7Chemotherapy, Adjuvant 7Mesna 6Immunohistochemistry 6Gemcitabine 6Carmustine 6Biopsy 6sargramostim 5pegfilgrastim 5etoposide phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × MLN 8237 × Sarcoma × Clear all
NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Children's Oncology Group

Phase 2 Completed
118 enrolled 24 charts
CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡